Abstract:CRISPR-Cas9 gene-editing technology has pushed the boundaries of genetic modification. The principle of this method is based on the purposeful defense system of DNA degradation and will be one of the most powerful instruments for gene editing shortly. The purpose of this study was to evaluate the capability of this approach to manage melanoma cells. The present study used EF1a-hsaCas9-U6-gRNA as a hybrid vector of sgRNA and Cas9 for the transfection of A-375 melanoma cells. Transfection efficiency was enhanced by examining the two concentrations of 4 and 8 µg/mL of hexadimethrine bromide (trade name Polybrene). The existence of Cas9 in transfected cells was detected by flow cytometry. The expression level of the metabisulfite-modified hTERT gene was measured by real-time PCR technique. The presence of telomerase in cells was determined by flow cytometry and western blotting analysis. The hTERT gene promoter methylation was also evaluated by HRM assay. Finally, the induction of apoptosis in transfected A375 cells was assessed using flow cytometry. The results showed that the presence of gRNA significantly increased the transfection efficiency (up to about 7.75 times higher). The hTERT expression levels in A-375 cells were significantly decreased at different concentrations of Polybrene (in a dose-dependent manner) and various amounts of transfection (P < 0.05). The expression of hTERT in basal cells was not significantly different from the group transfected without gRNA (P˃0.05) but was significantly higher than the group transfected with gRNA (P < 0.05). The results of flow cytometry and western blotting analysis showed a decrease in hTERT level compared to cells transfected without gRNA as well as basal cells. The methylation of hTERT gene promoter in the cells transfected with gRNA at a concentration of 80 μg/mL in the presence of both 4 μg/mL and 8 μg/mL of Polybrene was significantly increased compared to those transfected without sRNA (P < 0.05). The flow cytometry results indicated no significant difference in the induction of apoptosis in the transfected cells compared to the basal cells (P < 0.05). Evidence suggests that the designed CRISPR/Cas9 system reduces the expression of the hTERT gene and telomerase presence, thereby inhibiting the growth of melanoma cells.

Cancer Therapy with a CRISPR-assisted Telomerase-Activating Gene Expression System

Cancer gene therapy by NF-κB-activated cancer cell-specific expression of CRISPR/Cas9 targeting telomeres

Targeting Genomic Rearrangements in Tumor Cells Through Cas9-mediated Insertion of a Suicide Gene

CRISPR/Cas9-Mediated TERT Disruption in Cancer Cells

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Data from Reprogramming Murine Telomerase Rapidly Inhibits the Growth of Mouse Cancer Cells <i>in Vitro</i> and <i>in Vivo</i>

CRISPR-based molecule-regulatory expression platform for specific immunotherapy of cancer

Targeting telomerase for cancer therapy

Targeting Cancer with CRISPR/Cas9-Based Therapy

Inhibiting the growth of melanoma cells via hTERT gene editing using CRISPR-dCas9-dnmt3a system

Development of Cas13a-based therapy for cancer treatment

Tumor-specific transcriptional targeting of suicide gene therapy

Biomimetic gene editing system for precise tumor cell reprogramming and augmented tumor therapy

Potent Antitumor Effect of Trail Mediated by A Novel Adeno-Associated Viral Vector Targeting to Telomerase Activity for Human Hepatocellular Carcinoma

Harnessing the evolving CRISPR/Cas9 for precision oncology

CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy

Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy

Delivering Antisense Telomerase RNA by a Hybrid Adenovirus/ Adeno-Associated Virus Significantly Suppresses the Malignant Phenotype and Enhances Cell Apoptosis of Human Breast Cancer Cells

Telomere and Telomerase Therapeutics in Cancer

Telomerase: A Target for Anticancer Therapy

Therapeutic targeting at genome mutations of liver cancer by the insertion of HSV1 thymidine kinase through Cas9-mediated editing